Selenium in the Treatment of Graves’ Hyperthyroidism and Eye Disease
Based on the role of oxidative stress in the pathogenesis of Graves’ hyperthyroidism (GH) and Graves’ Orbitopathy (GO), a therapy with the antioxidant agent selenium has been proposed and a number of studies have been performed, both in vitro and in vivo. In GH, reactive oxygen species (ROS) contrib...
Main Authors: | Giulia Lanzolla, Michele Marinò, Claudio Marcocci |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-01-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2020.608428/full |
Similar Items
-
The change in the clinical presentation of Graves’ disease: a 30 years retrospective survey in an academic Brazilian tertiary center
by: Wanesa Pinto, et al.
Published: (2020-06-01) -
Hypo vs. hyperthyroid eye disease: is there any difference?
by: Bahram Eshraghi, et al.
Published: (2023-02-01) -
Antioxidant Therapy in Graves’ Orbitopathy
by: Giulia Lanzolla, et al.
Published: (2020-12-01) -
Evaluation of Quality of Life in the Brazilian Graves' Disease Population: Focus on Mild and Moderate Graves' Orbitopathy Patients
by: Danilo Villagelin, et al.
Published: (2019-04-01) -
Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves’ Disease Hyperthyroidism During Methimazole Treatment
by: Daniela Gallo, et al.
Published: (2022-06-01)